Background: We aimed to define the maximum tolerated dose (MTD) and characterize the toxicity of the combination of pegylated liposomal doxorubicin (PLD; Caelyxe) and weekly paclitaxel (wPTX), and to investigate pharmacokinetics of PLD in this combination. Methods: A phase I study was performed with an initial dose of 50 mg/m 2 wPTX and 30 mg/m 2 PLD.
Introduction
The majority of patients with advanced solid tumors receive palliative chemotherapy. Therefore, the development of effective therapeutic regimens that offer palliation of symptoms and also respect the quality of life of patients is of great importance [1, 2] . Doxorubicin and Taxol (paclitaxel formulated in Cremophor EL) are among the most potent cytotoxic drugs in use, with a definite role in the treatment of a variety of metastatic tumors. Unfortunately, they both have a poor toxicity profile, with detrimental effects on the daily life of patients treated. Myelosuppression and cardiotoxicity are the main side-effects of anthracyclines [3, 4] , while peripheral neuropathy is commonly encountered with paclitaxel [5, 6] . Alopecia is another unwanted adverse effect shared by both these agents.
Initial trials of the doxorubicin-paclitaxel combination suggested impressive response rates in metastatic breast cancer, but it failed to prove its merit in multicenter comparative studies [7, 8] . Moreover, the combination presented unacceptably high cardiac risk [9] , substantial myelosuppression, infectious complications and mucositis, which made its wide adoption in clinical practice problematic [10] .
Encapsulation of doxorubicin into liposomes coated with methoxypolyethyleneglycol alters favorably the toxicity profile of the active agent, and produces prolonged circulation and passive trapping in tumor due to an enhanced permeability and retention effect of tumor vessels [11, 12] . Polyethylene glycol-coated liposomal doxorubicin (PLD; Caelyxe) has been shown to be active against a variety of malignancies with a lower degree of toxicity [13 -15] . On the other hand, evidence is growing that favors weekly paclitaxel over the standard administration schedule [16] .
The efficacy and mild toxicity of PLD combined with the well tolerated weekly paclitaxel schedule make the combination an attractive alternative for the treatment of patients with metastatic cancer. We undertook this dose escalation study to identify the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of PLD combined with weekly paclitaxel (wPTX); data on the antitumor activity of the combination are also reported. This trial was conducted between April 1998 and September 2000 at the Oncology Department of the Ioannina University Hospital, Greece. It was approved by the local institutional review board and was performed in accordance with the Declaration of Helsinki and its amendments. All patients provided written, informed consent.
Patients and methods

End points
Primary end points were to determine the MTD and DLT of the PLD/wPTX combination. Secondary end points were to assess the spectrum of toxicities associated with its use and describe the pharmacokinetic profile and interactions of PLD when combined with wPTX. Recording of the antitumour activity of the combination was deemed appropriate in evaluable cases.
Eligibility criteria
Eligibility criteria for all patients included age >17 years, World Health Organization (WHO) performance status 0-2, life expectancy of at least 12 weeks, sufficient cardiac function defined by absence of symptoms and a left ventricular ejection fraction (LVEF) of at least 60%, adequate bone marrow [white blood cell count (WBC) >3.5 Â 10 9 , absolute neutrophil count (ANC) >1.5 Â 10 9 , platelet count >100 Â 10 9 ), renal (serum creatinine < _ 150 mmol/l) and hepatic [serum bilirubin <1.25Â upper limit of normal (ULN), serum transaminases <2Â ULN or <5Â ULN in the presence of liver metastases] functions, and absence of clinically relevant neuropathy, psychiatric illness, pregnancy or lactation. All patients were required to have histologically or cytologically proven locally advanced or metastatic solid tumors. Any previous chemotherapy should have been discontinued at least 4 weeks (6 weeks for nitrosoureas, melphalan, mitomycin C) before enrollment. Extended-field radiotherapy should have been stopped at least 6 weeks prior to study entry, whereas concurrent limited field radiotherapy was allowed.
Chemotherapy dose-escalation scheme: duration of treatment PLD was diluted in 250 ml dextrose/water solution and was infused intravenously over 1 h, followed by paclitaxel diluted in 500 ml of normal saline (NaCl 0.9%) infused over 1 h. Paclitaxel was re-administered on days 8 and 15. Treatment courses were repeated every 28 days.
Routine anti-allergy medication was always given prior to each treatment. This consisted of 32 mg oral methylprednisolone the day before, and a triplet of 16 mg dexamethasone, 0.1 mg/kg dimetindene maleate (antihistamine) and 100 mg ranitidine (H2 blocker) administered intravenously 30 min prior to treatment. Hematopoietic growth factors were only allowed for the management of complicated febrile neutropenia.
The initial dose levels were 30 mg/m 2 for PLD and 50 mg/m 2 for
wPXT. The paclitaxel dose was increased by 10 mg/m 2 in cohorts of a minimum of three patients in the absence of major toxicity. In the case of occurrence of a DLT event during the first two cycles in one patient, a minimum of six patients were to be treated at that dose level. Dose escalation could continue if no further DLTs were observed in all six patients (one of six). When two DLTs occurred within a maximum of six patients, it would be assumed that the MTD had been reached. Patients with measurable or evaluable disease who experience an objective response or clinical benefit continued therapy for a maximum of eight courses, toxicity permitting. Patients with progressive disease or unacceptable toxicity discontinued treatment and were dropped from the study.
Pharmacokinetics
The pharmacokinetics of PLD were to be studied only in patients treated at the estimated highest dose levels. For patients who consented to pharmacokinetic analysis, PLD was first given as a single agent and 4 weeks later was re-administered in combination with paclitaxel.
Each patient was sampled twice: when initially treated with PLD as a single agent and 4 weeks later when started on the combination. Heparinized blood (5 ml each) was collected from each patient at the following time points (in h): 0 (pre-dose), +0.15, +0.25, +0.5, +1, +2, +3, +8 and + 24, and also on the third, seventh, 14th and 21st day post-infusion of PLD. Blood samples were processed for plasma, centrifuged at 2500 g for 10 min at 48C and stored in a deep freeze at approximately À208C until analyzed. Samples were analyzed for total plasma doxorubicin at the Laboratory of Analytical Chemistry, European Environmental Research Institute, Ioannina, Greece.
We used a reversed-phase high-performance liquid chromatography assay developed by Gabizon to quantify doxorubicin, the active component of PLD, as described previously [17, 18] .
Pharmacokinetics of PLD were determined by non-compartmental analysis using the WinNonlin computer program, version 2.1 (Pharsight Corporation, Palo Alto, CA, USA). For statistical analysis the Prism 4 for Windows program (Graph Pad Software Inc., San Diego, CA) was used. Pharmacokinetic values obtained during single PLD administration and with the combination were compared for differences using the paired t-test.
Evaluation of toxicity
Toxicity was graded according to the National Cancer Institute Common Toxicity Criteria. Full blood count, biochemical analysis and clinical toxicity assessment were performed weekly during all treatment courses. Potential cardiotoxicity was monitored by echocardiographic evaluation of LVEF at baseline and every four cycles of treatment, or at any time upon clinical suspicion. Dose escalation and determination of DLT and MTD were performed on the basis of toxicity occurring during all cycles of chemotherapy.
DLT was defined as febrile neutropenia (fever >388C with grade 3 or 4 neutropenia), neutropenia grade > _ 2 resulting in a treatment delay of >2 weeks, any grade 4 thrombocytopenia or grade 3 thrombocytopenia associated with bleeding disorders, a relative decline of the LVEF by >20% and any grade 3 or 4 non-hematological toxicity except alopecia, nausea or vomiting.
The MTD was defined as the dose-level at which DLTs occurred in at least one-third of a six-patient cohort. Patients who did not complete a full course of treatment (one PLD infusion along with three weekly pulses of paclitaxel) for reasons not related to toxicity (withdrawal of consent, rapid disease progression) were replaced in the determination of DLT and MTD, but were included in all toxicity analyses.
Treatment modification and delays
Dose and/or schedule modifications were allowed to a limited extent on the basis of toxicity. Chemotherapy was only given in the presence of appropriate hematological reserves (WBC >3.0 Â 10 9 with ANC >1.0 Â 10 9 , platelet count >75 Â 10 9 ) and recovery of significant nonhematological toxicity. If this was not the case, treatment was delayed until hematological recovery, resolution of other organ toxicity or for a maximum of 2 weeks. In the case of a patient experiencing a DLT or other clinically significant toxic effects and further treatment being considered beneficial, therapy could be continued off-protocol at the next lowest dose level, based on the clinical judgment of the investigator.
Evaluation of response
Patients completing at least two cycles of treatment with at least one follow-up tumor assessment were considered evaluable for response. An initial tumor assessment for all patients was performed within 4 weeks prior to treatment initiation and thereafter every two cycles while on therapy and every 2 months thereafter until progression of disease. Chest X-rays, computed tomography scans, ultrasound imaging studies and clinical measurements were used as appropriate. Response was documented using the WHO response criteria for solid tumors [19] . For characterization of complete response (CR), total disappearance of all measurable and assessable disease was required; for partial response (PR) a >50% reduction in the size of all lesions as measured by the product of the greatest length and width of measurable lesions was required. Confirmation of objective responses was required in all cases at a minimum time interval of 4 weeks. Duration of response was calculated from the time the objective response was documented until the date of disease progression. Stable disease was measured from the start of the treatment until the criteria for progression were met, taking as reference the smallest measurements recorded after the treatment started.
Results
Forty-four patients with a variety of metastatic solid tumors were enrolled and received a total of 154 treatment cycles (one treatment cycle equals one infusion of PLD and three weekly pulses of paclitaxel) at different dose levels. The mean/median number of chemotherapy cycles administered per patient was 3.5/3, with >50% of the patients receiving at least three treatment cycles. Detailed study demographics are shown in Table 1 . In three subMTD dose levels more than six patients (seven, seven and nine) were treated. This was in accordance with the protocol design aiming to carry out a more reliable analysis of toxicity and obtain pharmacokinetics in consented patients.
Toxicity
Hematological toxicity
Hematological toxicity was mild (Tables 2 and 4 ) and consisted primarily of uncomplicated grade 3 neutropenia. In three cases it was characterized as DLT for causing a >2 week delay in chemotherapy re-administration. The median duration of all grade 3 uncomplicated neutropenic episodes was 5 days (range 1-8), whereas that of febrile neutropenic events was 3 days (range 1 -5). Overall, no major ablative effect was observed in the erythropoietic or thrombopoietic blood lineages.
Non-hematological toxicity
The five most common non-hematological side-effects observed in this patient population were mucositis, nausea/ vomiting, neurotoxicity, palmar -plantar erythrodysesthesia and fatigue. However, the majority of these events were mild and easy to manage, if treatment was needed at all. No cardiac toxicity was seen with repeat echocardiogram, and alopecia was negligible without the use of a scalp cooling system. Detailed data on the non-hematological toxicity profile are depicted in Table 3 .
Serious non-hematological reactions were seen in three patients, who developed thromboembolic events not directly attributable to the protocol treatment. Interestingly, two of these patients had predisposing factors for vascular thrombosis. A 56-year-old female patient with metastatic thyroid cancer treated at the 30/50 cohort developed subclavicular venous thrombosis at a site of pre-existing extensive infiltration by malignant disease. The event occurred at cycle 3 and, although a serious adverse event, it was attributed to the underlying primary tumor and was not characterized as a DLT. In the 30/70 cohort a 74-year-old female with metastatic breast cancer and long-standing atrial fibrillation developed a thromboembolic occlusion of the right popliteal artery 2 months after her last chemotherapy course. An amputation below the knee was carried out. In view of her past medical history and the echocardiographic evidence of a left atrial thrombus, this serious adverse event was not considered treatment-related. Further chemotherapy was given uneventfully off-study in the form of carboplatin plus paclitaxel. One patient in the 30/90 dose level developed thrombosis of the internal jugular vein which was characterized as a DLT.
DLT and MTD
The dose escalation, number of patients included in each cohort, the DLTs and serious adverse events are concisely presented in Table 4 . DLTs consisted of protracted grade 3 neutropenia, febrile neutropenia and thromboembolic event spread over the entire escalation range. In all cases, patients developing a DLT were taken off protocol treatment.
MTDs were determined to be dose levels 30/90 and 35/80 mg/m 2 (for PLD/wPTX). Two patients who received treatment at the dose level 30/90 developed DLTs: the first a grade 3 neutropenia at cycle 2 delaying treatment for >2 weeks, and the second a jugular deep venous thrombosis at first cycle. The thrombotic event was characterized as a DLT since it occurred in the absence of local tumor infiltration or compression.
In addition, two patients treated at 35/80 developed a DLT. The first developed grade 3 palmar-plantar erythrodysesthesia at cycle 4. The skin reaction improved after 8 days and the patient received off-study therapy for another two uneventful cycles at lower doses. The second patient had a protracted grade 3 neutropenia delaying treatment for >2 weeks at cycle 2. The patient elected not to receive further chemotherapy.
Dose modifications and delays
Dose reductions due to treatment-related toxic effects were made based on medical judgment in eight out of 44 patients, in 20 out of 154 chemotherapy courses (13%). Sixteen patients were dropped from the study at some time during their management for reasons other than progressive disease or clinical deterioration, including patient's request (four), completion of therapy (three), toxicity related to chemotherapy (six) or adverse events thought to be unrelated to treatment (three). Chemotherapy had to be delayed by one or more weeks in 46 out of 462 weekly pulses of chemotherapy (10%).
Efficacy
Thirty-four patients were evaluable for tumor response. Three CRs and nine PRs were documented among 34 evaluable cases. Another 15 patients had disease stabilization, and only five exhibited progressive disease from the outset despite treatment. The median duration both of CR and PR was 5 months, while that of stable disease was 3 months. The three CRs had metastatic breast, bladder and ovarian cancer. As seen in Table 5 , objective responses occurred at almost all dose levels, whereas patients treated at the recommended doses of 30/80 and 35/70 derived a similar benefit.
Pharmacokinetic analyses
Pharmacokinetic sampling was performed in seven patients, one each at 35/50, 35/60, 35/70 and 30/80, and three at 30/70. The median area under the concentration curve (AUC) of liposomal doxorubicin at single administration of PLD was 1427 [±589 standard deviation (SD)], whereas the median AUC of the drug in combination was 2316 (±886 SD) (Figure 1 ). The observed difference was statistically significant (paired t-test P = 0.03), with a median 53.5%, mean 77.3% increase of PLD AUC at the combined administration. A similar difference was also observed in the plasma clearance of PLD, which was decreased in the combination in comparison with the singleagent administration. Pharmacokinetic data are summarized in Table 6 .
Discussion
Preserving the quality of life of cancer patients with metastatic, incurable disease who are offered palliative cytotoxic chemotherapy is of principal importance [20] . Taxanes and anthracyclines produce toxicities that preclude prolonged use and even compromise the quality of life of treated patients. Doxorubicin has been in clinical use for more than two decades in cancer treatment and has established lasting landmarks in the treatment of several malignancies, such as lymphomas, breast cancer and sarcomas. However, the classical cumulative dose-related cardiotoxicity sets an upper limit for its safe clinical use [21] . To reduce cardiomyopathy, administration schedules producing low peak plasma drug concentrations have been adopted and novel liposomal formulations have been attempted [22] . The antimicrotubule agent Taxol (paclitaxel formulated in Cremophor EL) has been evaluated in clinical trials for over 10 years and is currently being used in the treatment of certain tumor types, including breast, ovarian and non-small-cell lung cancer [23] . The combination of these two drugs is a potent chemotherapy regimen against a number of solid tumors. However, initial reports pointed to an alarming rate of cardiotoxicity along with poorly tolerated toxicity [24, 25] . The increased occurrence of toxicities with the combination is partially attributed to reduced clearance of doxorubicin in the presence of paclitaxel [26] .
We developed a novel combination regimen of these two active agents with the primary aim of ameliorating toxicity. For each drug we used the most suitable pharmacological approach with regard to producing the most favorable toxicity profile. For doxorubicin, this is the novel PLD (Caelyxe) formulation, and for paclitaxel it is the weekly schedule [27, 28] . PLD, primarily developed to optimize pharmacokinetics and abrogate unacceptable clinical toxicity of doxorubicin, is now gaining acceptance as a useful alternative to non-encapsulated standard doxorubicin for its favorable clinical profile [13, 14] .
In our study, the favorable clinical profile of each of the drugs was maintained in the combination. Myelosuppression was minimal and well tolerated. Grade 3-4 neutropenia occurred in 19 of 154 treatment cycles (12%) and was uncomplicated. Only three episodes of febrile neutropenia, of short duration, occurred (2%). There was no relevant anemia or thrombocytopenia. Alopecia, neurotoxicity, diarrhea and mucositis were mild, a striking finding for a pre-treated patient population receiving a combination of anthracyclines plus taxane. Although palmar -plantar erythrodysesthisa is a common side-effect associated with PLD, it was less common in our study. A grade 1-2 palmar-plantar erythrodysesthisa was encountered in treated patients in 15 of 154 treatment cycles (10%), the difference probably being explained by the lower PLD doses administered and the non-overlapping toxicity with paclitaxel. There was no evidence of clinically manifested heart failure. Admittedly, some concern may be raised by the occurrence of three cardiovascular events in our study. Careful examination of the clinical setting and patient's past medical history in two of these events implies that they were not related to the study treatment, and implicates past medical history and progressive disease as main causative factors. Still, as one event was not otherwise explained and in view of possible 'synergy' between the chemotherapy being studied, we must consider further a possible procoagulant activity of this combination. Increasing clinical experience with the study chemotherapy will allow safe conclusions to be drawn on the importance and causes of this phenomenon.
The pharmacokinetics of PLD are characterized by a very long circulating half-life, slow plasma clearance and a reduced volume of distribution compared with conventional liposomal doxorubicin or free doxorubicin. In keeping with the already published evidence for the conventional doxorubicin and paclitaxel combination regimens [26, 29] , PLD clearance was reduced by weekly paclitaxel, resulting in a significant increase of systemic tissue exposure. Yet the mechanism of the observed drug to drug interaction is not known. It should be emphasized that this finding should not be interpreted by merely projecting what is known about conventional doxorubicin plus paclitaxel combinations. In the case of PLD, circulating doxorubicin is mostly found in the form of liposome-encapsulated drug, which is primarily untaken in peripheral and tumor tissues [30, 31] . An observed objective response rate of $ 35% lasting a median of 5 months is promising, and supports existing evidence of enhanced activity of both PLD and weekly taxanes. Although premature conclusions about the antitumour efficacy of the regimen should not be drawn in view of the significant number of patients who were either chemonaïve or not previously exposed to anthracyclines/taxanes, it does indicate a need for assessment to continue in phase II studies. Supporting indirect evidence for the efficacy of the regimen is also provided by the presence of major or minor responses in patients treated at all dose levels, as well as in patients with 'chemotherapy-resistant' tumors such as renal, thyroid, cancer of unknown primary site and mesothelioma.
Based on toxicity, response and pharmacokinetic data, no superiority for either of the two recommended dosing regimens could be established from this study. In conclusion, we suggest that Caelyx given every 4 weeks in combination with three weekly pulses of paclitaxel at doses of either 30/80 or 35/70 mg/m 2 is a safe and active combination that may offer patients with advanced cancer an optimized palliative chemotherapeutic option. Further evaluation in phase II studies in patients with specific tumor types and survival-efficacy primary end points is warranted.
